Calithera Biosciences To Offer Initial Results From Phase 2 Study Of CB-839 In Combo With Opdivo At SITC Meeting: 'Achieved confirmed responses in melanoma patients progressing on PD-1/PD-L1 therapy'
Paul Quintaro